{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:19:21Z","timestamp":1791317961656,"version":"4.3.1"},"reference-count":23,"publisher":"American Diabetes Association","issue":"1","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:p>Reduced coronary flow reserve (CFR), an indicator of coronary microvascular dysfunction, is seen in type 2 diabetes mellitus (T2DM) and predicts cardiac mortality. Since aldosterone plays a key role in vascular injury, the aim of this study was to determine whether mineralocorticoid receptor (MR) blockade improves CFR in individuals with T2DM. Sixty-four men and women with well-controlled diabetes on chronic ACE inhibition (enalapril 20 mg\/day) were randomized to add-on therapy of spironolactone 25 mg, hydrochlorothiazide (HCTZ) 12.5 mg, or placebo for 6 months. CFR was assessed by cardiac positron emission tomography at baseline and at the end of treatment. There were significant and similar decreases in systolic blood pressure with spironolactone and HCTZ but not with placebo. CFR improved with treatment in the spironolactone group as compared with the HCTZ group and with the combined HCTZ and placebo groups. The increase in CFR with spironolactone remained significant after controlling for baseline CFR, change in BMI, race, and statin use. Treatment with spironolactone improved coronary microvascular function, raising the possibility that MR blockade could have beneficial effects in preventing cardiovascular disease in patients with T2DM.<\/jats:p>","DOI":"10.2337\/db14-0670","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T09:05:09Z","timestamp":1408093509000},"page":"236-242","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":124,"title":["Mineralocorticoid Receptor Blockade Improves Coronary Microvascular Function in Individuals With Type 2 Diabetes"],"prefix":"10.2337","volume":"64","author":[{"given":"Rajesh","family":"Garg","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2550-6097","authenticated-orcid":false,"given":"Ajay D.","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Baimas-George","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Foster","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi V.","family":"Shah","sequence":"additional","affiliation":[{"name":"Noninvasive Cardiovascular Imaging Program, Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jerosch-Herold","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Kwong","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo F.","family":"Di Carli","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"Noninvasive Cardiovascular Imaging Program, Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail K.","family":"Adler","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,8,14]]},"reference":[{"key":"2022031223022716600_B1","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"2022031223022716600_B2","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"JAMA"},{"key":"2022031223022716600_B3","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0735-1097(03)00166-9","article-title":"Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes","volume":"41","author":"Di Carli","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022031223022716600_B4","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.112.120402","article-title":"Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus","volume":"126","author":"Murthy","year":"2012","journal-title":"Circulation"},{"key":"2022031223022716600_B5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/clc.22025","article-title":"Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications","volume":"35","author":"Markowitz","year":"2012","journal-title":"Clin Cardiol"},{"key":"2022031223022716600_B6","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.CIR.0000097000.51723.6F","article-title":"Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II\/NG-nitro-L-arginine methyl ester-induced myocardial injury","volume":"108","author":"Oestreicher","year":"2003","journal-title":"Circulation"},{"key":"2022031223022716600_B7","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1093\/eurheartj\/eht095","article-title":"Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity","volume":"34","author":"Sch\u00e4fer","year":"2013","journal-title":"Eur Heart J"},{"key":"2022031223022716600_B8","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1093\/eurheartj\/eht158","article-title":"Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity","volume":"34","author":"Pojoga","year":"2013","journal-title":"Eur Heart J"},{"key":"2022031223022716600_B9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2337\/db12-0905","article-title":"Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease","volume":"62","author":"Bender","year":"2013","journal-title":"Diabetes"},{"key":"2022031223022716600_B10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"key":"2022031223022716600_B11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amjcard.2013.02.060","article-title":"Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus","volume":"112","author":"Rao","year":"2013","journal-title":"Am J Cardiol"},{"key":"2022031223022716600_B12","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","article-title":"Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells","volume":"269","author":"Hatakeyama","year":"1994","journal-title":"J Biol Chem"},{"key":"2022031223022716600_B13","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","article-title":"Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion","volume":"102","author":"Caprio","year":"2008","journal-title":"Circ Res"},{"key":"2022031223022716600_B14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lomb\u00e8s","year":"1995","journal-title":"Circulation"},{"key":"2022031223022716600_B15","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/en.2011-2098","article-title":"Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis","volume":"153","author":"Bienvenu","year":"2012","journal-title":"Endocrinology"},{"key":"2022031223022716600_B16","doi-asserted-by":"crossref","first-page":"H281","DOI":"10.1152\/ajpheart.00304.2008","article-title":"Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats","volume":"295","author":"Viel","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022031223022716600_B17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Leopold","year":"2007","journal-title":"Nat Med"},{"key":"2022031223022716600_B18","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","article-title":"Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart","volume":"143","author":"Rocha","year":"2002","journal-title":"Endocrinology"},{"key":"2022031223022716600_B19","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","article-title":"Aldosterone-induced inflammation in the rat heart: role of oxidative stress","volume":"161","author":"Sun","year":"2002","journal-title":"Am J Pathol"},{"key":"2022031223022716600_B20","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223022716600_B21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"2022031223022716600_B22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","article-title":"Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles","volume":"51","author":"Swaminathan","year":"2008","journal-title":"Diabetologia"},{"key":"2022031223022716600_B23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/13543776.2014.854772","article-title":"Mineralocorticoid receptor modulators: a patent review (2007\u20132012)","volume":"24","author":"Collin","year":"2014","journal-title":"Expert Opin Ther Pat"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/64\/1\/236\/577575\/236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/64\/1\/236\/577575\/236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:42:45Z","timestamp":1667392965000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/64\/1\/236\/34670\/Mineralocorticoid-Receptor-Blockade-Improves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,8,14]]},"published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db14-0670","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718533782.793552951","asserted-by":"object"}]},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,14]]}}}